Nandita S. Scott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nandita S. Scott has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Emily S. Lau
Heart and Vascular Institute, Mass General Brigham
6 shared publications Amy A. Sarma
Massachusetts General Hospital
4 shared publications- Michael C. Honigberg
Mass General Brigham, Heart and Vascular Institute , Boston, MA 02114
4 shared publications Daniela R. Crousillat
University of South Florida
3 shared publications- Garima Sharma
Inova Schar Heart and Vascular, Inova Health System, Falls Church, Virginia, USA
3 shared publications - Amy A. Sarma
Cardiology Division Department of Medicine Massachusetts General Hospital Boston MA
2 shared publications
Latest Publications
- 1 May 2026
- Published by Springer Nature
- p. 63-78
Pregnancy as a Window into Future Cardiovascular Health
- 1 May 2026
- Published by Springer Nature
- p. 63-78
Pregnancy as a Window into Future Cardiovascular Health
- Open Access
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e041885
What Every Cardiologist Should Know About Contraception and Reproductive Planning in 2025
Recent studies have shown that maternal mortality continues to increase for all racial and ethnic groups in the United States. The recent changes in reproductive legal policies combined with unacceptably high morbidity and mortality rates have made it crucial for every cardiologist to understand and engage with reproductive planning. The risk of cardiovascular complications during pregnancy is prohibitively high for patients in the modified World Health Organization Risk Class IV with maternal cardiovascular event rates of >40%, and pregnancy is not recommended. It is critical that cardiologists partner with primary care providers, Obstetrics and Gynecology, Complex Family Planning subspecialist, Maternal‐Fetal Medicine specialists, Anesthesia, and Pharmacist and Nursing to implement available contraception strategies and understand termination options that can be offered to these high‐risk patients. The aim of this article is to review risks and advantages of available contraception and pregnancy termination options as it pertains to these high‐risk cardiac patients.
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e041885
Open AccessWhat Every Cardiologist Should Know About Contraception and Reproductive Planning in 2025
Recent studies have shown that maternal mortality continues to increase for all racial and ethnic groups in the United States. The recent changes in reproductive legal policies combined with unacceptably high morbidity and mortality rates have made it crucial for every cardiologist to understand and engage with reproductive planning. The risk of cardiovascular complications during pregnancy is prohibitively high for patients in the modified World Health Organization Risk Class IV with maternal cardiovascular event rates of >40%, and pregnancy is not recommended. It is critical that cardiologists partner with primary care providers, Obstetrics and Gynecology, Complex Family Planning subspecialist, Maternal‐Fetal Medicine specialists, Anesthesia, and Pharmacist and Nursing to implement available contraception strategies and understand termination options that can be offered to these high‐risk patients. The aim of this article is to review risks and advantages of available contraception and pregnancy termination options as it pertains to these high‐risk cardiac patients.
- 17 January 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 136 (2) , 180-190
Venous Endothelial Cell Transcriptomic Profiling Implicates METAP1 in Preeclampsia
BACKGROUND: Preeclampsia is a hypertensive disorder of pregnancy characterized by systemic endothelial dysfunction. The pathophysiology of preeclampsia remains incompletely understood. This study used human venous endothelial cell (EC) transcriptional profiling to investigate potential novel mechanisms underlying EC dysfunction in preeclampsia. METHODS: Venous ECs were isolated from postpartum patients with severe preeclampsia and those with normotensive pregnancy using a J wire–based technique in the antecubital vein followed by CD144 (vascular endothelial cadherin) magnetic bead isolation. Venous EC transcriptomes were compared between preeclamptic and normotensive individuals. Differentially expressed genes were carried forward for genetic validation using expression quantitative trait loci from the Genotype-Tissue Expression project as exposures for vascular-specific Mendelian randomization. Functional validation of the top candidate was performed in human umbilical vein ECs using gain- and loss-of-function genetic approaches. RESULTS: Seventeen individuals with preeclampsia and 7 normotensive controls were included. Pairwise analysis yielded 14 protein-coding genes nominally differentially expressed in participants with preeclampsia. Mendelian randomization revealed a significant association between higher genetically predicted METAP1 (methionyl aminopeptidase 1) expression in aortic and tibial arterial tissues and greater risk of preeclampsia. METAP1 overexpression in human umbilical vein ECs decreased angiogenesis, with a 66% decrease in tube formation ( P =7.9×10 −3 ) and 72% decrease in cell proliferation ( P =2.9×10 −2 ). Furthermore, METAP1 overexpression decreased VEGFA expression and increased expression of multiple preeclampsia-related genes, for example, FLT1 , INHBA , and IL1B . Conversely, METAP1 knockdown produced opposite effects on tube formation, cell proliferation, and inflammation-related gene expression. CONCLUSIONS: In a cohort of early postpartum individuals, we observed greater METAP1 expression in venous ECs of women with preeclampsia versus normotensive delivery. Mendelian randomization supported a causal relationship between greater vascular METAP1 expression and higher preeclampsia risk, and functional experiments demonstrated antiangiogenic and proinflammatory effects of METAP1 in human ECs consistent with alterations observed in preeclampsia. Ex vivo EC transcriptomics can identify novel mechanisms underlying preeclampsia pathophysiology, with implications for prevention and treatment.
- 17 January 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 136 (2) , 180-190
Venous Endothelial Cell Transcriptomic Profiling Implicates METAP1 in Preeclampsia
BACKGROUND: Preeclampsia is a hypertensive disorder of pregnancy characterized by systemic endothelial dysfunction. The pathophysiology of preeclampsia remains incompletely understood. This study used human venous endothelial cell (EC) transcriptional profiling to investigate potential novel mechanisms underlying EC dysfunction in preeclampsia. METHODS: Venous ECs were isolated from postpartum patients with severe preeclampsia and those with normotensive pregnancy using a J wire–based technique in the antecubital vein followed by CD144 (vascular endothelial cadherin) magnetic bead isolation. Venous EC transcriptomes were compared between preeclamptic and normotensive individuals. Differentially expressed genes were carried forward for genetic validation using expression quantitative trait loci from the Genotype-Tissue Expression project as exposures for vascular-specific Mendelian randomization. Functional validation of the top candidate was performed in human umbilical vein ECs using gain- and loss-of-function genetic approaches. RESULTS: Seventeen individuals with preeclampsia and 7 normotensive controls were included. Pairwise analysis yielded 14 protein-coding genes nominally differentially expressed in participants with preeclampsia. Mendelian randomization revealed a significant association between higher genetically predicted METAP1 (methionyl aminopeptidase 1) expression in aortic and tibial arterial tissues and greater risk of preeclampsia. METAP1 overexpression in human umbilical vein ECs decreased angiogenesis, with a 66% decrease in tube formation ( P =7.9×10 −3 ) and 72% decrease in cell proliferation ( P =2.9×10 −2 ). Furthermore, METAP1 overexpression decreased VEGFA expression and increased expression of multiple preeclampsia-related genes, for example, FLT1 , INHBA , and IL1B . Conversely, METAP1 knockdown produced opposite effects on tube formation, cell proliferation, and inflammation-related gene expression. CONCLUSIONS: In a cohort of early postpartum individuals, we observed greater METAP1 expression in venous ECs of women with preeclampsia versus normotensive delivery. Mendelian randomization supported a causal relationship between greater vascular METAP1 expression and higher preeclampsia risk, and functional experiments demonstrated antiangiogenic and proinflammatory effects of METAP1 in human ECs consistent with alterations observed in preeclampsia. Ex vivo EC transcriptomics can identify novel mechanisms underlying preeclampsia pathophysiology, with implications for prevention and treatment.
- 20 November 2024
- Published by Elsevier in Trends in Cardiovascular Medicine
Cardio obstetrics: Bridging heart and pregnancy health
- 20 November 2024
- Published by Elsevier in Trends in Cardiovascular Medicine
Cardio obstetrics: Bridging heart and pregnancy health
- Open Access
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , 1272-1284
Coronary Microvascular Function Following Severe Preeclampsia
BACKGROUND: Preeclampsia is a pregnancy-specific hypertensive disorder associated with an imbalance in circulating proangiogenic and antiangiogenic proteins. Preclinical evidence implicates microvascular dysfunction as a potential mediator of preeclampsia-associated cardiovascular risk. METHODS: Women with singleton pregnancies complicated by severe antepartum-onset preeclampsia and a comparator group with normotensive deliveries underwent cardiac positron emission tomography within 4 weeks of delivery. A control group of premenopausal, nonpostpartum women was also included. Myocardial flow reserve, myocardial blood flow, and coronary vascular resistance were compared across groups. sFlt-1 (soluble fms-like tyrosine kinase receptor-1) and PlGF (placental growth factor) were measured at imaging. RESULTS: The primary cohort included 19 women with severe preeclampsia (imaged at a mean of 15.3 days postpartum), 5 with normotensive pregnancy (mean, 14.4 days postpartum), and 13 nonpostpartum female controls. Preeclampsia was associated with lower myocardial flow reserve (β, −0.67 [95% CI, −1.21 to −0.13]; P =0.016), lower stress myocardial blood flow (β, −0.68 [95% CI, −1.07 to −0.29] mL/min per g; P =0.001), and higher stress coronary vascular resistance (β, +12.4 [95% CI, 6.0 to 18.7] mm Hg/mL per min/g; P =0.001) versus nonpostpartum controls. Myocardial flow reserve and coronary vascular resistance after normotensive pregnancy were intermediate between preeclamptic and nonpostpartum groups. Following preeclampsia, myocardial flow reserve was positively associated with time following delivery ( P =0.008). The sFlt-1/PlGF ratio strongly correlated with rest myocardial blood flow ( r =0.71; P <0.001), independent of hemodynamics. CONCLUSIONS: In this exploratory cross-sectional study, we observed reduced coronary microvascular function in the early postpartum period following preeclampsia, suggesting that systemic microvascular dysfunction in preeclampsia involves coronary microcirculation. Further research is needed to establish interventions to mitigate the risk of preeclampsia-associated cardiovascular disease.
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , 1272-1284
Open AccessCoronary Microvascular Function Following Severe Preeclampsia
BACKGROUND: Preeclampsia is a pregnancy-specific hypertensive disorder associated with an imbalance in circulating proangiogenic and antiangiogenic proteins. Preclinical evidence implicates microvascular dysfunction as a potential mediator of preeclampsia-associated cardiovascular risk. METHODS: Women with singleton pregnancies complicated by severe antepartum-onset preeclampsia and a comparator group with normotensive deliveries underwent cardiac positron emission tomography within 4 weeks of delivery. A control group of premenopausal, nonpostpartum women was also included. Myocardial flow reserve, myocardial blood flow, and coronary vascular resistance were compared across groups. sFlt-1 (soluble fms-like tyrosine kinase receptor-1) and PlGF (placental growth factor) were measured at imaging. RESULTS: The primary cohort included 19 women with severe preeclampsia (imaged at a mean of 15.3 days postpartum), 5 with normotensive pregnancy (mean, 14.4 days postpartum), and 13 nonpostpartum female controls. Preeclampsia was associated with lower myocardial flow reserve (β, −0.67 [95% CI, −1.21 to −0.13]; P =0.016), lower stress myocardial blood flow (β, −0.68 [95% CI, −1.07 to −0.29] mL/min per g; P =0.001), and higher stress coronary vascular resistance (β, +12.4 [95% CI, 6.0 to 18.7] mm Hg/mL per min/g; P =0.001) versus nonpostpartum controls. Myocardial flow reserve and coronary vascular resistance after normotensive pregnancy were intermediate between preeclamptic and nonpostpartum groups. Following preeclampsia, myocardial flow reserve was positively associated with time following delivery ( P =0.008). The sFlt-1/PlGF ratio strongly correlated with rest myocardial blood flow ( r =0.71; P <0.001), independent of hemodynamics. CONCLUSIONS: In this exploratory cross-sectional study, we observed reduced coronary microvascular function in the early postpartum period following preeclampsia, suggesting that systemic microvascular dysfunction in preeclampsia involves coronary microcirculation. Further research is needed to establish interventions to mitigate the risk of preeclampsia-associated cardiovascular disease.
- Open Access
- 18 March 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (4) , 100901
Recommendations for the Management of High-Risk Cardiac Delivery
- 18 March 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (4) , 100901
Open AccessRecommendations for the Management of High-Risk Cardiac Delivery
- 4 August 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (9) , 1065-1073
Cardio-Obstetrics: A Focused Review
Purpose of Review Cardiovascular disease is the leading cause of maternal mortality in the USA. All cardiovascular care providers should have a foundational knowledge on the management of pregnant individuals with heart disease. This focused review touches on several key cardio-obstetric themes. Recent Findings Many individuals with cardiovascular disease can safely undergo pregnancy, but should have counseling preconception to optimize cardiac status. There are several cardiovascular conditions that are high risk for maternal mortality and morbidity. These individuals should be adequately counseled preconception and offered reliable birth control. Summary The approach to a high-risk pregnant patient with cardiac disease is best managed by a multidisciplinary team to address potential maternal and fetal complications. Identification of at risk individuals can be estimated preconception with several risk scores. The development of risk scores to stratify and identify those at elevated risk during pregnancy is an area of continued research and development.
- 4 August 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (9) , 1065-1073
Cardio-Obstetrics: A Focused Review
Purpose of Review Cardiovascular disease is the leading cause of maternal mortality in the USA. All cardiovascular care providers should have a foundational knowledge on the management of pregnant individuals with heart disease. This focused review touches on several key cardio-obstetric themes. Recent Findings Many individuals with cardiovascular disease can safely undergo pregnancy, but should have counseling preconception to optimize cardiac status. There are several cardiovascular conditions that are high risk for maternal mortality and morbidity. These individuals should be adequately counseled preconception and offered reliable birth control. Summary The approach to a high-risk pregnant patient with cardiac disease is best managed by a multidisciplinary team to address potential maternal and fetal complications. Identification of at risk individuals can be estimated preconception with several risk scores. The development of risk scores to stratify and identify those at elevated risk during pregnancy is an area of continued research and development.
- 3 August 2023
- Published by Springer Nature
- p. 303-313
Native Valvular Heart Disease in Pregnancy
- Top Cited Papers
- 14 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (7) , 597-610
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
- 14 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (7) , 597-610
Top Cited PapersRethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.